Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS S

Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS S

Item
http://www.wikidata.org/entity/Q34805650
Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized TrialsAlirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsPCSK9 inhibition: current concepts and lessons from human genetics.Targeting PCSK9 for therapeutic gainsPCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.An evaluation of alirocumab for the treatment of hypercholesterolemia.Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications.PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab.Alirocumab: A Review in Hypercholesterolemia.Monoclonal Antibodies for Lipid Management.PCSK9 in chronic kidney disease.Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.PCSK9 inhibitors: A new era of lipid lowering therapy.
P2860

Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS S

Item
http://www.wikidata.org/entity/Q34805650
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of alirocu ...... onale of the ODYSSEY OPTIONS S
@ast
Efficacy and safety of alirocu ...... onale of the ODYSSEY OPTIONS S
@en
Efficacy and safety of alirocu ...... y controlled with atorvastatin
@nl
type
label
Efficacy and safety of alirocu ...... onale of the ODYSSEY OPTIONS S
@ast
Efficacy and safety of alirocu ...... onale of the ODYSSEY OPTIONS S
@en
Efficacy and safety of alirocu ...... y controlled with atorvastatin
@nl
prefLabel
Efficacy and safety of alirocu ...... onale of the ODYSSEY OPTIONS S
@ast
Efficacy and safety of alirocu ...... onale of the ODYSSEY OPTIONS S
@en
Efficacy and safety of alirocu ...... y controlled with atorvastatin
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Efficacy and safety of alirocu ...... onale of the ODYSSEY OPTIONS S
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932